Multigene Panels in Prostate Cancer Risk Assessment Executive Summary

ثبت نشده
چکیده

The Agency for Healthcare Research and Quality (AHRQ), through its Evidencebased Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist publicand private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments. AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality. The full report and this summary are available at www.effectivehealthcare. ahrq.gov/reports/final.cfm. Background

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Multigene panels in prostate cancer risk assessment.

OBJECTIVES The aim of this review is to identify, synthesize, and appraise the literature on the analytic validity, clinical validity, and clinical utility of commercially available single nucleotide polymorphism (SNP) panel tests for assessing the risk of prostate cancer. DATA SOURCES MEDLINE®, Cochrane CENTRAL, Cochrane Database of Systematic Reviews, and Embase, from the beginning of each ...

متن کامل

Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer

When Policy Topic is not covered The following genetic and protein biomarkers for the diagnosis of prostate cancer are considered investigational:  Kallikrein markers (eg, 4KscoreTM Test)  Metabolomic profiles (eg, ProstarixTM)  PCA3 testing  TMPRSS fusion genes  Candidate gene panels  Mitochondrial DNA mutation testing (eg, Prostate Core Mitomics TestTM)  Gene hypermethylation testing (...

متن کامل

Pnm-9: An Assessment of Knowledge, Attitude and Practice of Ahvaz Male Pensioners towards Prevention of Prostate Cancer in the Year 2010

Background: Prostate cancer is the second most common cancer among men after lung cancer. Prevention of death from prostate cancer by increasing knowledge and attitude is possible. The purpose of this study was to assess knowledge, attitude and practice of men pensioners in Ahvaz city towards prevention of prostate cancer. Materials and Methods: This descriptive study was conducted on 1000 pens...

متن کامل

Gene expression analysis for prostate cancer management.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these se...

متن کامل

Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management

BACKGROUND Multigene panels can be a cost- and time-effective alternative to sequentially testing multiple genes, especially with a mixed family cancer phenotype. However, moving beyond our single-gene testing paradigm has unveiled many new challenges to the clinician. The purpose of this article is to familiarize the reader with some of the challenges, as well as potential opportunities, of ex...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012